Endothelin-1 regulates parathyroid hormones expression of human parathyroid cells

Clinical Nephrology

Volumn 66, Issue 1, 2006, Pages 25-31

  Chang, J M ^a,b   Kuo, M C ^a,b   Chen, H M ^a,c   Lee, C H ^a,b   Lai, Y H ^a,b   Chen, H C ^a,b   Hwang, S J ^a,b  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Endothelin 1; Hyperparathyroidism; Parathyroid Hormone; Uremia

Indexed keywords

CALCITONIN; CALCIUM; ENDOTHELIN 1; MESSENGER RNA; PARATHYROID HORMONE;

ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; GENE EXPRESSION REGULATION; GENERAL ANESTHESIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PARATHYROID HYPERPLASIA; PATHOGENESIS; PROTEIN SECRETION; PROTEIN SYNTHESIS; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY HYPERPARATHYROIDISM; SURGICAL APPROACH; UREMIA;

EID: 33745893200     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp66025     Document Type: Article

References (26)

1. Boarder MR, Marmot D. Endothelin-1 stimulation of noradrenalin and adrenaline release from adrenal chromaffin cells. Biochem Pharmacol. 1991; 41: 521-526.
2. Chang JM, Lai YH, Tsai JH. Interaction between extracellular calcium and endothelin-1 influences parathyroid hormone secretion from bovine parathyroid cells through the increase of intracellular calcium. Miner Electrolyte Metab. 1997; 23: 113-120.
3. Chang JM, Hwang SJ, Tsai JC, Lai YH. In vivo effect of endothelin-1 on plasma calcium and parathyroid hormone concentrations. J Endocrinol. 2000; 165: 179-184.
4. Chang JM, Lin SP, Kuo HT, Tsai JC, Tomino Y, Lai YH, Chen HC. 7-84 Parathyroid hormone fragments are proportionally increased with the severity of uremic hyperparathyroidism. Clin. Nephrol. 2005; in press.
5. Cozza EN, Gomez-Sanchez CE, Foecking MF, Chiou S. Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion. J Clin Invest. 1989; 84: 1032-1035.
6. Dykxhoorn DM, Novina CD, Sharp PA. Killing the messenger: Short RNAs that silence gene expression. Nat Rev Mol Cell Biol. 2003; 4: 457-467.
7. Fujii Y, Moreira JE, Orlando C, Maggi M, Aurbach GD, Brandi ML, Sakaguchi K. Endothelin as an autocrine factor in the regulation of parathyroid cells. Proc Natl Acad Sci USA. 199 1; 88: 4235-4239.
8. Glorieux G, Vanholder R. Blunted response to vitamin D in uremia. Kidney Int. 2001; Suppl 78: 182-185.
9. Hörl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant. 2004; 19 (Suppl 5): v2-v8.
10. Hruska, KA, Teitelbau, SL. Renal osteodystrophy. N Engl J Med. 1995; 333: 166-174.
11. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab. 1999; 84: 4287-4290.
12. Kosaka T, Suzuki N, Matsumoto H, Itoh Y, Yasuhara T, Onda H, Fujino M. Synthesis of the vasoconstrictor peptide endothelin in kidney cells. FEBS Lett. 1989; 249: 42-46.
13. Koyama H, Tabata T, Nishzawa Y, Inoue T, Morii H, Yamaji T. Plasma endothelin levels in patients with uremia. Lancet. 1989; 333: 991-992.
14. Lai KN, Li PKT, Woo KS, Lui SF, Leung JCK, Law E, Nicholis MG. Vasoactive hormone in uremic patients on continuous ambulatory peritoneal dialysis. Clin Nephrol. 1991; 35: 218-223.
15. Masaki T. Endothelins: homeostatic and compensatory actions in the circulatory and endocrine systems. Endocrine Rev. 1993; 14: 256-268.
16. Miller WL, Redfield MH, Burnett JC Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 1989; 83: 317-320.
17. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005; 67: 760-771.
18. Nagy A. Cre recombinase: the universal reagent for genome tailoring. Genesis. 2000; 26: 99-109.
19. Napoli C, Liguori A, Sorice P, di Benedetto A, Ciafre S, Posca T, di Ieso N, D'Armiento FP. Relations between vasoactive hormones and diastolic function in hypertensive uremic patients. J Int Med. 1996; 240: 389-394.
20. Nomura K, Yamashita J, Ogawa M. Endothelin-1 is involved in the transient hypoparathyroidism seen in patients undergoing thyroid surgery. J Endocrinol. 1994; 143: 343-351.
21. Rabelink TJ, Kaasjager KA, Boer P, Stroes EG, Braam B, Koomans HA. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994; 46: 381-476.
22. Remuzzi G, Benigni A. Endothelins in the control of cardiovascular and renal function. Lancet. 1993; 342: 589-593.
23. Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Ren Physiol. 2005; 288: F253-F264.
24. Slatopolsky E, Robson AM, Elkan I, Bricker NS. Control of phosphate excretion in uremic man. J Clin Invest. 1969; 47: 1865-1874.
25. Sorensen SS, Madsen JK, Pedersen EB. Systemic and renal effect of intravenous infusion of endothelin-1 in healthy human volunteers. Am J Physiol. 1994; 266: F411-17418.
26. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Tazaki Y, Goto K, Masaki T. A novel potent constrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.